First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Loss‐of‐function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations